

**Alpha-, Beta-, and Gamma-Synuclein: Developmental
Localisation and Response to Cellular Insult in Neurons
and Oligodendrocytes.**

by

Marian Quilty BSc (Hons)

Submitted in fulfilment of the
requirement for the Degree of
Doctor of Philosophy

Menzies Research Institute (September 2009)

COPYRIGHT STATEMENT

This thesis contains no material which has been accepted for a degree or diploma by the Institute or any other University or institution, except by way of background information duly acknowledged in the thesis, and to the best of my knowledge and belief no material previously published or written by another person except where due acknowledgement is made in the text of the thesis, nor does the thesis contain any material that infringes copyright.

Marian Quilty

STATEMENT OF AUTHORITY OF ACCESS

This thesis may be made available for loan and limited copying in accordance with the *Copyright Act 1968*.

Marian Quilty

Part of the work presented in this thesis has been published or submitted for publication as follows;

Quilty, M.C., King, A.E., Gai, W-P., Pountney, D., West, A.K., Vickers, J.C., Dickson, T.C. Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection. *Experimental Neurology*. 199(2) (2006), 249-56.

Quilty, M.C., W-P. Gai, D.L. Pountney, A.K. West, and J.C. Vickers. Localisation of alpha-, beta- and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. *Experimental Neurology*. 182 (2003), 195-207.

Pountney, D.L., Lowe, R., **Quilty M.C.**, Vickers, J.C., Voelcker N.H., Gai, W.-P. Annular alpha-synuclein species from purified multiple system atrophy inclusions. *Journal of Neurochemistry* 90 (20) (2004), 502-12.

SUMMARY

Alpha-synuclein is a highly conserved, ubiquitously expressed protein in the vertebrate brain. It was discovered in 1988 and was purported to play a role in song learning, implicating a role in synaptic plasticity. Alpha-synuclein came under increased scrutiny shortly thereafter as the non-amyloid component isolated from plaques from Alzheimer's disease brains. Following this discovery, alpha-synuclein was further characterised as the main component in numerous additional inclusion bodies found in several neurodegenerative disease leading to speculation that alpha-synuclein was involved in disease pathogenesis.

Two decades later little is known about the normal function of alpha-synuclein in neuronal cells, however numerous studies have determined alpha-synuclein is able to form fibrils and aggregates, and that these may provide the neurotoxic mechanism by which alpha-synuclein exerts its effect in disease states. Other studies have demonstrated the formation of fibrillar aggregates of alpha-synuclein is a neuroprotective mechanism. The issues of the cellular role and neurotoxicity of alpha-synuclein remain contentious. This thesis provides evidence indicating a developmentally regulated role for alpha-synuclein in neurons and oligodendrocytes, as well as roles in neuroprotection, plasticity and regeneration. This thesis has demonstrated synuclein isoforms have a distinct pattern of localisation during neuronal development, indicating alpha-, beta- and gamma-synuclein also have distinct functionality within neuronal development, and that these functions may alter as neurons develop.

Alpha-synuclein immunoreactive neuritic abnormalities were shown to be caused by physical insult to the axon, leading to the accumulation of alpha-synuclein protein in neuronal processes, and were associated with neurofilament pathology mirroring that seen in some disease states containing aggregated forms of alpha-synuclein. It was demonstrated alpha-synuclein is involved in regenerative sprouting following axonal injury, further implying a role for alpha-synuclein in aspects of growth cone development and/or maturation as well as neuronal plasticity.

Additionally, synuclein isoforms were shown to have a distinct pattern of localisation during oligodendroglial development, indicating alpha-, beta- and gamma-synuclein also have distinct functionality within oligodendrocytes, and these functions may alter throughout development. In this case exogenous alpha-synuclein was demonstrated to be taken up by oligodendrocytes, and incorporated into cytoplasmic inclusions, along with endogenous alpha-synuclein, implying a mechanism by which alpha-synuclein interacts with oligodendrocytes in disease states leading to the formation of glial cytoplasmic inclusions. Finally, and importantly this thesis demonstrated an increase in alpha-synuclein in response to stressful stimuli is beneficial to neuronal survival as part of a normal neuronal response in a subpopulation of neurons. This finding is somewhat contentious as many of the studies into the role and mechanism of alpha-synuclein in disease states support its neurotoxicity, yet this thesis contradicts this, providing evidence for a neuroprotective affect of alpha-synuclein.

ACKNOWLEDGEMENTS

I would like to thank my supervisors, Prof James Vickers, and Prof Adrian West for giving me the opportunity to perform this study and for their constant encouragement over the years. Secondly I would like to thank Dr. Tracey Dickson for her continued support, encouragement and assistance through this process. Additionally I thank my husband Bill and all my family for their support over the years.

I would also like to thank my fellow students and colleagues from the Discipline of Pathology and Neurorepair group for providing a friendly work environment. In particular I would like to thank, Graeme McCormack, Deb Orchard, Dr. Bernadette Bellette, Dr. Justin Dittman, Dr. Emma Woodhall, Dr. Anna King, Dr. Jerome Staal and Vicki Carroll for their friendship, constant assistance and council.

Specifically I would like to thank Dr. Anna King and Dr. Tracey Dickson for their assistance with the oxidative stress chapter of this thesis. They provided additional experimental support and research that contributed to the publication of this chapter as a journal article.

Finally I would like to thank my sponsors for their financial support, which has made this project possible, and for taking a supportive interest in my research. In particular I would like to thank Royal Hobart Hospital Research Foundation B.G Thomas bequest for funding this research, as well as collaborating researchers at Flinders University, Adelaide, Dr. Dean Pountney and Dr. Wei-Ping Gai.

TABLE OF CONTENTS

1	INTRODUCTION	1
1.1	THE DISCOVERY OF SYNUCLEINS	1
1.2	THE SYNUCLEIN FAMILY	2
1.3	CELLULAR AND DEVELOPMENTAL LOCALISATION OF SYNUCLEINS	12
1.4	NEURODEGENERATIVE DISEASES AS SYNUCLEINOPATHIES	15
1.5	PUTATIVE DISEASE MECHANISMS	32
1.6	THE CELLULAR ROLE OF SYNUCLEINS	38
1.7	PROJECT AIMS	47
2	MATERIALS AND METHODS	50
2.1	GENERAL ANIMAL CONDITIONS AND CARE	50
2.2	CULTURE TECHNIQUES	50
2.3	FLUORESCENCE IMMUNOCYTOCHEMISTRY	52
2.4	MICROSCOPY AND ANALYSIS	53
3	LOCALISATION OF ALPHA-, BETA- AND GAMMA-SYNUCLEIN DURING NEURONAL DEVELOPMENT AND ALTERATIONS ASSOCIATED WITH THE NEURONAL RESPONSE TO AXONAL TRAUMA.	55
3.1	INTRODUCTION	55
3.2	MATERIALS AND METHODS	59
3.3	RESULTS	61
3.4	DISCUSSION	79
3.5	SUMMARY	83
4	ALPHA-SYNUCLEIN IS UPREGULATED IN NEURONS IN RESPONSE TO CHRONIC OXIDATIVE STRESS AND IS ASSOCIATED WITH NEUROPROTECTION.	84
4.1	INTRODUCTION	84
4.2	MATERIALS AND METHODS	88
4.3	RESULTS	91
4.4	DISCUSSION	107

5	THE DEVELOPMENTAL LOCALISATION OF ALPHA-SYNUCLEIN IN OLIGODENDROCYTES <i>IN VITRO</i> AND THE UPTAKE OF EXOGENOUS ALPHA-SYNUCLEIN.	111
5.1	INTRODUCTION	111
5.2	MATERIALS AND METHODS	116
5.3	RESULTS	118
5.4	DISCUSSION	131
5.5	SUMMARY	136
6	DISCUSSION	137
6.1	SYNUCLEIN ISOFORMS AND THEIR ROLE IN DEVELOPMENT	140
6.2	PATHOLOGICAL RELEVANCE OF ALPHA-SYNUCLEIN	144
6.3	IMPLICATIONS FOR SYNUCLEINOPATHIES	152
6.4	FUTURE DIRECTION AND FURTHER EXPERIMENTATION	155
7	REFERENCES	159
8	APPENDIX – SOLUTIONS	199
8.1	GENERAL SOLUTIONS	199
8.2	CELL CULTURE SOLUTIONS	199
8.3	IMMUNOHISTOCHEMISTRY AND IMMUNOCYTOCHEMISTRY SOLUTIONS	200

ABBREVIATIONS

aa	amino acid
AD	Alzheimer's disease
ALS	amyotrophic lateral sclerosis
ATP	adenosine triphosphate
A53T	missense mutant alpha-synuclein
A30P	missense mutant alpha-synuclein
BAD	Bcl-associated death promoter
CNS	central nervous system
CSF	cerebrospinal fluid
CSP-alpha	cysteine-string protein alpha
DA	dopamine
DAI	diffuse axonal injury
DAT	dopamine transporter
DHR-123	dihydrorhodamine – 1,2,3
DIV	days <i>in vitro</i>
DLB	dementia with Lewy bodies
DLBD	diffuse Lewy body dementia
DMEM	Dulbecco's Modified Eagle's Medium
EDTA	ethylenediamine tetra acetic acid
ER	endoplasmic reticulum
ERK	extracellular signal regulated kinase
E46K	missense mutant alpha-synuclein
GCI	glial cytoplasmic inclusion
GNI	glial nuclear inclusion
GRK	G protein coupled receptor kinase
HBSS	Hank's Balance Salt Solution
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
IR	immunoreactivity
kDa	kilo dalton
LB	Lewy body
LBVAD	Lewy body variant of Alzheimer's disease
LN	Lewy neurite
LRRK2	Leucine-rich repeat kinase 2
MAO	mono-amine oxidase

MAP	microtubule-associated protein
MPTP	1-methyl-1-phenyl-1,2,3,6-tetrahydropyridine
mRNA	messenger ribonucleic acid
MSA	multiple systems atrophy
NA	noradrenaline
NAC	non-amyloid component
NACP	non-amyloid component precursor protein
NCI	neuronal cytoplasmic inclusion
NFH	neurofilament heavy chain
NFL	neurofilament light chain
NFM	neurofilament medium chain
NFT	neurofibrillary tangle
NNI	neuronal nuclear inclusion
OE	olfactory epithelium
ORN	olfactory receptor neuron
PARK1	alpha-synuclein gene
PBS	phosphate buffered saline
PD	Parkinson's disease
PFA	paraformaldehyde
PINK1	phosphatase and tensin (PTEN) homologue - induced putative kinase 1
PKC	protein kinase C
PM	plasma membrane
PNP-14	phosphoneuroprotein 14 kDa
RNA	ribonucleic acid
ROS	reactive oxygen species
SEM	standard error of the mean
SN	substantia nigra
SNCA	alpha-synuclein gene
SNpc	Substantia nigra pars compacta
SNpr	Substantia nigra pars reticulata
SOD	superoxide dismutase
TH	Tyrosine hydroxylase
WT	wild type